US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ENGENE HOLDINGS INC

9.74

+0.19001.99%

Post-market: 9.740.00000.00%16:10 EST

Volume:130.03K

Turnover:1.25M

Market Cap:652.43M

PE:-4.24

High:9.81

Open:9.36

Low:9.24

Close:9.55

52wk High:12.25

52wk Low:2.65

Shares:66.98M

Float Shares:37.33M

Volume Ratio:0.26

T/O Rate:0.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2947

EPS(LYR):-2.2947

ROE:-53.28%

ROA:-28.90%

PB:3.89

PE(LYR):-4.24

Loading ...

Overview Company News Filings

enGene Holdings nimmt am Guggenheim Emerging Outlook: Biotech Summit teil

Jefferies Initiates Coverage on enGene With Buy Rating, $28 Price Target

MT Newswires Live

enGene initiated with a Buy at Jefferies

enGene Holdings Issues 2026 Warrants to Purchase Common Shares

enGene Holdings - Secures up to $100 Mln for Detalimogene Development & Commercialization for Bladder Cancer

THOMSON REUTERS

enGene Announces Expanded $125 Million Debt Facility With Hercules Capital, Inc.

THOMSON REUTERS

enGene Secures Expanded $125 Million Debt Facility from Hercules Capital

EnGene Fiscal 2025 Loss Widens

MT Newswires Live

enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate

enGene reports FY net loss of USD 117.3 million, more than double year-on-year

enGene Holdings Inc - Cash and Marketable Securities Plus Proceeds From Nov Financing Expected to Provide Cash Runway Into 2H 2028

THOMSON REUTERS

Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update

EnGene Says US FDA Selects Detalimogene for Manufacturing Pilot Program

MT Newswires Live

BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness

enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial

enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

THOMSON REUTERS

enGene Holdings - FDA Selects Detalimogene Voraplasmid to Participate in Chemistry, Manufacturing, & Controls Development & Readiness Pilot Pprogram

THOMSON REUTERS

enGene Holdings Inc. to Present at Piper Sandler 37th Annual Healthcare Conference

enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC Filing

enGene Holdings Inc : Leerink Partners Cuts Target Price to $19 From $21

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ENGN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENGN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENGN\",,,,,undefined,":{"symbol":"ENGN","market":"US","secType":"STK","nameCN":"ENGENE HOLDINGS INC","latestPrice":9.74,"timestamp":1770670800000,"preClose":9.55,"halted":0,"volume":130034,"hourTrading":{"tag":"盘后","latestPrice":9.74,"preClose":9.74,"latestTime":"16:10 EST","volume":1226,"amount":11941.24,"timestamp":1770671404284,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01989528795811513,"floatShares":37332800,"shares":66984661,"eps":-2.294663,"marketStatus":"Post-Mkt","change":0.19,"latestTime":"02-09 17:22:39 EST","open":9.36,"high":9.81,"low":9.24,"amount":1248901.300102,"amplitude":0.059686,"askPrice":10.85,"askSize":100,"bidPrice":8.73,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-2.294663,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770685200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":9.55,"postHourTrading":{"tag":"盘后","latestPrice":9.74,"preClose":9.74,"latestTime":"16:10 EST","volume":1226,"amount":11941.24,"timestamp":1770671404284,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.264395},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENGN\",,,,,undefined,":{"symbol":"ENGN","floatShares":37332800,"roa":"-28.90%","roe":"-53.28%","lyrEps":-2.294663,"volumeRatio":0.264395,"shares":66984661,"dividePrice":0,"high":9.81,"amplitude":0.059686,"preClose":9.55,"low":9.24,"week52Low":2.65,"pbRate":"3.89","week52High":12.25,"institutionHeld":0,"latestPrice":9.74,"committee":0.818182,"eps":-2.294663,"divideRate":0,"volume":130034,"delay":0,"ttmEps":-2.294663,"open":9.36,"prevYearClose":9.03,"prevWeekClose":9.55,"prevMonthClose":9.53,"prevQuarterClose":9.03,"fiveDayClose":10,"twentyDayClose":8.81,"sixtyDayClose":8.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENGN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-22","symbol":"ENGN","fiscalQuarterEnding":"2025/10","expectedEps":-0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1766379600000,"reportTimeType":"post","actualEps":-0.73},{"market":"US","date":"2025-09-11","symbol":"ENGN","fiscalQuarterEnding":"2025/07","expectedEps":-0.49,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1757563200000,"reportTimeType":"post","actualEps":-0.57},{"market":"US","date":"2025-06-12","symbol":"ENGN","fiscalQuarterEnding":"2025/04","expectedEps":-0.5,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1749700800000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-03-10","symbol":"ENGN","fiscalQuarterEnding":"2025/01","expectedEps":-0.37,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741579200000,"reportTimeType":"post","actualEps":-0.48},{"market":"US","date":"2024-12-19","symbol":"ENGN","fiscalQuarterEnding":"2024/10","expectedEps":-0.4,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1734584400000,"reportTimeType":"post","actualEps":-0.34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENGN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENGN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.4167,"hold":0.0833,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4167,"analysts":12,"updateTime":1769835600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ENGN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ENGN","date":"2026-02-06","current":-4.244632,"percent":0.38764,"low":-11.074501,"twenty":-6.405623,"median":-3.7399,"eighty":-2.573804,"high":-1.741293,"avg":-4.396537,"sd":1.810882,"marketCap":593484096},"quantilePoints":[{"date":"2023-11-24","current":-7.107113,"twenty":-7.362609,"median":-7.152095,"eighty":-7.017149,"marketCap":183264010},{"date":"2023-12-01","current":-6.8912,"twenty":-7.362609,"median":-7.170087,"eighty":-7.020748,"marketCap":177696496},{"date":"2023-12-08","current":-6.666292,"twenty":-8.564557,"median":-7.174585,"eighty":-6.887602,"marketCap":171897002},{"date":"2023-12-15","current":-6.641012,"twenty":-7.798032,"median":-7.107113,"eighty":-6.607942,"marketCap":171245139},{"date":"2023-12-22","current":-6.504358,"twenty":-7.362609,"median":-6.814731,"eighty":-6.515153,"marketCap":167721366},{"date":"2023-12-29","current":-7.296036,"twenty":-7.276244,"median":-6.747259,"eighty":-6.432387,"marketCap":188135585},{"date":"2024-01-05","current":-6.405398,"twenty":-7.70447,"median":-6.814731,"eighty":-6.412595,"marketCap":165169589},{"date":"2024-01-12","current":-7.251054,"twenty":-7.438178,"median":-6.882204,"eighty":-6.486365,"marketCap":186975686},{"date":"2024-01-19","current":-7.197076,"twenty":-7.362609,"median":-6.882204,"eighty":-6.515153,"marketCap":185583808},{"date":"2024-01-26","current":-6.837222,"twenty":-7.314029,"median":-6.823728,"eighty":-6.515153,"marketCap":176304617},{"date":"2024-02-02","current":-1.959536,"twenty":-7.276604,"median":-6.810233,"eighty":-6.462974,"marketCap":195790917},{"date":"2024-02-09","current":-1.845771,"twenty":-7.256092,"median":-6.76975,"eighty":-6.369412,"marketCap":184423909},{"date":"2024-02-16","current":-3.645108,"twenty":-7.218667,"median":-6.747259,"eighty":-3.756551,"marketCap":364208223},{"date":"2024-02-23","current":-6.848243,"twenty":-7.197076,"median":-6.729266,"eighty":-3.686899,"marketCap":684255939},{"date":"2024-03-01","current":-6.376994,"twenty":-7.189879,"median":-6.715257,"eighty":-3.782089,"marketCap":637170146},{"date":"2024-03-08","current":-6.913094,"twenty":-7.175485,"median":-6.740159,"eighty":-4.788696,"marketCap":690735636},{"date":"2024-03-15","current":-7.043277,"twenty":-7.155487,"median":-6.747259,"eighty":-6.236267,"marketCap":726936601},{"date":"2024-03-22","current":-7.516207,"twenty":-7.197076,"median":-6.792241,"eighty":-6.288445,"marketCap":775747691},{"date":"2024-03-28","current":-7.279742,"twenty":-7.276523,"median":-6.837222,"eighty":-6.349337,"marketCap":751342146},{"date":"2024-04-05","current":-6.925044,"twenty":-7.26113,"median":-6.876032,"eighty":-6.379076,"marketCap":714733828},{"date":"2024-04-12","current":-6.874373,"twenty":-7.240258,"median":-6.870151,"eighty":-6.391004,"marketCap":709504068},{"date":"2024-04-19","current":-5.983407,"twenty":-7.197076,"median":-6.842733,"eighty":-6.391004,"marketCap":617547460},{"date":"2024-04-26","current":-6.289752,"twenty":-7.193478,"median":-6.810233,"eighty":-6.342947,"marketCap":649165336},{"date":"2024-05-03","current":-6.546128,"twenty":-7.177285,"median":-6.792241,"eighty":-6.351434,"marketCap":675625879},{"date":"2024-05-10","current":-6.153019,"twenty":-7.167527,"median":-6.747259,"eighty":-6.342947,"marketCap":635053046},{"date":"2024-05-17","current":-6.063287,"twenty":-7.153064,"median":-6.743709,"eighty":-6.259918,"marketCap":625791856},{"date":"2024-05-24","current":-5.614629,"twenty":-7.135657,"median":-6.708499,"eighty":-6.098325,"marketCap":579485904},{"date":"2024-05-31","current":-4.486576,"twenty":-7.133587,"median":-6.688278,"eighty":-6.063287,"marketCap":463059513},{"date":"2024-06-07","current":-3.360659,"twenty":-7.131951,"median":-6.661794,"eighty":-5.648813,"marketCap":346853625},{"date":"2024-06-14","current":-4.27293,"twenty":-7.118439,"median":-6.651549,"eighty":-5.484732,"marketCap":441009060},{"date":"2024-06-21","current":-3.406965,"twenty":-7.110292,"median":-6.643683,"eighty":-5.017274,"marketCap":384687244},{"date":"2024-06-28","current":-3.508666,"twenty":-7.107113,"median":-6.634163,"eighty":-4.27293,"marketCap":396170446},{"date":"2024-07-05","current":-3.516489,"twenty":-7.107113,"median":-6.621073,"eighty":-3.815858,"marketCap":397053769},{"date":"2024-07-12","current":-3.5204,"twenty":-7.093203,"median":-6.587237,"eighty":-3.642484,"marketCap":397495431},{"date":"2024-07-15","current":-3.547781,"twenty":-7.089725,"median":-6.572786,"eighty":-3.63199,"marketCap":400587062},{"date":"2024-08-02","current":-3.446081,"twenty":-7.089604,"median":-6.558336,"eighty":-3.589657,"marketCap":389103860},{"date":"2024-08-09","current":-2.777205,"twenty":-7.088397,"median":-6.52142,"eighty":-3.527005,"marketCap":313579728},{"date":"2024-08-16","current":-2.307818,"twenty":-7.080829,"median":-6.504358,"eighty":-3.517271,"marketCap":260580338},{"date":"2024-08-23","current":-2.370403,"twenty":-7.05836,"median":-6.454878,"eighty":-3.458598,"marketCap":267646923},{"date":"2024-08-30","current":-2.573804,"twenty":-7.039722,"median":-6.405398,"eighty":-3.383305,"marketCap":290613326},{"date":"2024-09-06","current":-2.554246,"twenty":-7.025502,"median":-6.379484,"eighty":-3.290156,"marketCap":288405018},{"date":"2024-09-13","current":-2.400727,"twenty":-6.984161,"median":-6.343733,"eighty":-3.031456,"marketCap":293704957},{"date":"2024-09-20","current":-2.587735,"twenty":-6.954602,"median":-6.302571,"eighty":-2.628566,"marketCap":316583531},{"date":"2024-09-27","current":-1.987785,"twenty":-6.936182,"median":-6.238965,"eighty":-2.585538,"marketCap":243185673},{"date":"2024-10-04","current":-2.349201,"twenty":-6.925044,"median":-6.153019,"eighty":-2.573804,"marketCap":287401250},{"date":"2024-10-11","current":-2.479311,"twenty":-6.921741,"median":-6.080379,"eighty":-2.554246,"marketCap":303318858},{"date":"2024-10-18","current":-3.361165,"twenty":-6.921741,"median":-5.983407,"eighty":-2.554246,"marketCap":411204866},{"date":"2024-10-25","current":-3.216598,"twenty":-6.91854,"median":-5.659496,"eighty":-2.56605,"marketCap":393518635},{"date":"2024-10-31","current":-3.137087,"twenty":-6.914183,"median":-5.580446,"eighty":-2.572253,"marketCap":383791208},{"date":"2024-11-08","current":-3.035891,"twenty":-6.895579,"median":-5.443712,"eighty":-2.573804,"marketCap":371410846},{"date":"2024-11-15","current":-3.304095,"twenty":-6.884003,"median":-4.928824,"eighty":-2.580062,"marketCap":404222931},{"date":"2024-11-22","current":-3.195938,"twenty":-6.875939,"median":-4.2302,"eighty":-2.584756,"marketCap":390991104},{"date":"2024-11-29","current":-3.604285,"twenty":-6.87184,"median":-3.830846,"eighty":-2.585538,"marketCap":440948247},{"date":"2024-12-06","current":-3.600118,"twenty":-6.869976,"median":-3.719091,"eighty":-2.585538,"marketCap":440438480},{"date":"2024-12-13","current":-2.745924,"twenty":-6.85689,"median":-3.63199,"eighty":-2.586856,"marketCap":335936294},{"date":"2024-12-20","current":-2.483415,"twenty":-6.84163,"median":-3.604285,"eighty":-2.585538,"marketCap":303820988},{"date":"2024-12-27","current":-5.676196,"twenty":-6.836881,"median":-3.618138,"eighty":-2.585538,"marketCap":312996790},{"date":"2025-01-03","current":-6.526701,"twenty":-6.831143,"median":-3.666853,"eighty":-2.585977,"marketCap":359895332},{"date":"2025-01-10","current":-7.488141,"twenty":-6.86986,"median":-3.752745,"eighty":-2.587735,"marketCap":412911075},{"date":"2025-01-17","current":-6.480478,"twenty":-6.874373,"median":-4.2302,"eighty":-2.598578,"marketCap":357346498},{"date":"2025-01-24","current":-6.739327,"twenty":-6.870995,"median":-4.27293,"eighty":-2.60436,"marketCap":371619968},{"date":"2025-01-31","current":-6.563679,"twenty":-6.869918,"median":-5.380342,"eighty":-2.617897,"marketCap":361934399},{"date":"2025-02-07","current":-5.870333,"twenty":-6.868974,"median":-5.443712,"eighty":-2.624253,"marketCap":323701892},{"date":"2025-02-14","current":-5.777887,"twenty":-6.852345,"median":-5.580446,"eighty":-2.62701,"marketCap":318604225},{"date":"2025-02-21","current":-5.657707,"twenty":-6.84163,"median":-5.580446,"eighty":-2.628136,"marketCap":311977257},{"date":"2025-02-28","current":-5.398857,"twenty":-6.836711,"median":-5.546263,"eighty":-2.689586,"marketCap":297703787},{"date":"2025-03-07","current":-4.908892,"twenty":-6.833612,"median":-5.507012,"eighty":-2.739661,"marketCap":270686149},{"date":"2025-03-14","current":-3.949849,"twenty":-6.818849,"median":-5.443712,"eighty":-2.748264,"marketCap":272725216},{"date":"2025-03-21","current":-3.846555,"twenty":-6.800468,"median":-5.398857,"eighty":-2.766253,"marketCap":265593087},{"date":"2025-03-28","current":-3.506936,"twenty":-6.792928,"median":-5.371072,"eighty":-2.784959,"marketCap":242143410},{"date":"2025-04-04","current":-3.32236,"twenty":-6.792241,"median":-5.209343,"eighty":-2.829161,"marketCap":229399020},{"date":"2025-04-11","current":-2.953209,"twenty":-6.790707,"median":-4.908892,"eighty":-2.913999,"marketCap":203910240},{"date":"2025-04-17","current":-2.923677,"twenty":-6.772715,"median":-4.84418,"eighty":-2.93549,"marketCap":201871137},{"date":"2025-04-25","current":-2.953209,"twenty":-6.747259,"median":-4.251565,"eighty":-2.945826,"marketCap":203910240},{"date":"2025-05-02","current":-2.761251,"twenty":-6.747259,"median":-3.986833,"eighty":-2.932537,"marketCap":190656074},{"date":"2025-05-09","current":-2.502845,"twenty":-6.744419,"median":-3.927701,"eighty":-2.802203,"marketCap":172813928},{"date":"2025-05-16","current":-2.510228,"twenty":-6.739826,"median":-3.830846,"eighty":-2.747484,"marketCap":173323704},{"date":"2025-05-23","current":-3.167317,"twenty":-6.735303,"median":-3.794841,"eighty":-2.747484,"marketCap":218693732},{"date":"2025-05-30","current":-2.923677,"twenty":-6.725113,"median":-3.752745,"eighty":-2.752109,"marketCap":201871137},{"date":"2025-06-06","current":-2.672654,"twenty":-6.707049,"median":-3.661979,"eighty":-2.752109,"marketCap":184538767},{"date":"2025-06-13","current":-2.07932,"twenty":-6.698654,"median":-3.63591,"eighty":-2.725522,"marketCap":166091903},{"date":"2025-06-20","current":-2.104911,"twenty":-6.688278,"median":-3.604285,"eighty":-2.672654,"marketCap":168136111},{"date":"2025-06-27","current":-2.296849,"twenty":-6.667466,"median":-3.604285,"eighty":-2.62092,"marketCap":183467671},{"date":"2025-07-03","current":-2.431205,"twenty":-6.666527,"median":-3.583451,"eighty":-2.587296,"marketCap":194199763},{"date":"2025-07-11","current":-2.35443,"twenty":-6.659095,"median":-3.561833,"eighty":-2.580062,"marketCap":188067139},{"date":"2025-07-18","current":-2.35443,"twenty":-6.655298,"median":-3.539958,"eighty":-2.554246,"marketCap":188067139},{"date":"2025-07-25","current":-2.360828,"twenty":-6.649599,"median":-3.52355,"eighty":-2.534434,"marketCap":188578191},{"date":"2025-08-01","current":-2.424807,"twenty":-6.646743,"median":-3.5204,"eighty":-2.507148,"marketCap":193688711},{"date":"2025-08-08","current":-2.284053,"twenty":-6.64208,"median":-3.515844,"eighty":-2.48321,"marketCap":182445567},{"date":"2025-08-15","current":-2.309644,"twenty":-6.630054,"median":-3.506936,"eighty":-2.47065,"marketCap":184489775},{"date":"2025-08-22","current":-2.501582,"twenty":-6.623896,"median":-3.454767,"eighty":-2.461358,"marketCap":199821335},{"date":"2025-08-29","current":-3.039006,"twenty":-6.619926,"median":-3.440489,"eighty":-2.468312,"marketCap":242749704},{"date":"2025-09-05","current":-3.198953,"twenty":-6.619121,"median":-3.41834,"eighty":-2.469592,"marketCap":255526005},{"date":"2025-09-12","current":-3.269576,"twenty":-6.618902,"median":-3.418342,"eighty":-2.470386,"marketCap":309697518},{"date":"2025-09-19","current":-3.755157,"twenty":-6.607902,"median":-3.41834,"eighty":-2.472354,"marketCap":355692198},{"date":"2025-09-26","current":-3.512912,"twenty":-6.592605,"median":-3.443285,"eighty":-2.476912,"marketCap":332746511},{"date":"2025-10-03","current":-4.399246,"twenty":-6.573102,"median":-3.455255,"eighty":-2.481157,"marketCap":416701015},{"date":"2025-10-10","current":-4.804582,"twenty":-6.560473,"median":-3.482585,"eighty":-2.483004,"marketCap":455094844},{"date":"2025-10-17","current":-4.755942,"twenty":-6.551011,"median":-3.507507,"eighty":-2.493964,"marketCap":450487584},{"date":"2025-10-24","current":-4.250623,"twenty":-6.534472,"median":-3.514055,"eighty":-2.501348,"marketCap":402623278},{"date":"2025-10-31","current":-3.761518,"twenty":-6.52409,"median":-3.516489,"eighty":-2.50234,"marketCap":356294726},{"date":"2025-11-07","current":-3.253497,"twenty":-6.521235,"median":-3.517125,"eighty":-2.506072,"marketCap":308174461},{"date":"2025-11-14","current":-5.747343,"twenty":-6.512214,"median":-3.517762,"eighty":-2.509426,"marketCap":544394099},{"date":"2025-11-21","current":-4.499699,"twenty":-6.505293,"median":-3.5204,"eighty":-2.510823,"marketCap":426216021},{"date":"2025-11-28","current":-5.501905,"twenty":-6.50383,"median":-3.527462,"eighty":-2.515041,"marketCap":521145952},{"date":"2025-12-05","current":-5.803257,"twenty":-6.499968,"median":-3.539958,"eighty":-2.525832,"marketCap":549690322},{"date":"2025-12-12","current":-6.297452,"twenty":-6.489408,"median":-3.551776,"eighty":-2.533925,"marketCap":596500933},{"date":"2025-12-19","current":-5.767958,"twenty":-6.465686,"median":-3.579074,"eighty":-2.53967,"marketCap":546346707},{"date":"2025-12-26","current":-5.39637,"twenty":-6.439801,"median":-3.600118,"eighty":-2.547781,"marketCap":633005046},{"date":"2026-01-02","current":-5.156532,"twenty":-6.42501,"median":-3.604285,"eighty":-2.550334,"marketCap":604871488},{"date":"2026-01-09","current":-4.853878,"twenty":-6.414394,"median":-3.618138,"eighty":-2.554246,"marketCap":569369618},{"date":"2026-01-16","current":-5.26503,"twenty":-6.406521,"median":-3.645108,"eighty":-2.554246,"marketCap":617598574},{"date":"2026-01-23","current":-6.075913,"twenty":-6.405623,"median":-3.661979,"eighty":-2.563689,"marketCap":712716793},{"date":"2026-01-30","current":-5.864627,"twenty":-6.408096,"median":-3.687226,"eighty":-2.572253,"marketCap":687932468},{"date":"2026-02-06","current":-5.059454,"twenty":-6.405623,"median":-3.7399,"eighty":-2.573804,"marketCap":593484096}],"updateTime":1770675760029},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENGN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608645763","title":"enGene Holdings nimmt am Guggenheim Emerging Outlook: Biotech Summit teil","url":"https://stock-news.laohu8.com/highlight/detail?id=2608645763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608645763?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:01","pubTimestamp":1770210115,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. wird am Mittwoch, den 11. Februar 2026, um 14:30 Uhr  an einem Fireside-Chat im Rahmen des Guggenheim Emerging Outlook: Biotech Summit 2026 teilnehmen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL78sDKh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2607488610","title":"Jefferies Initiates Coverage on enGene With Buy Rating, $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2607488610","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607488610?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:29","pubTimestamp":1769776192,"startTime":"0","endTime":"0","summary":"enGene Holdings (ENGN) has an average rating of Buy and mean price target of $31.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2607016330","title":"enGene initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2607016330","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607016330?lang=en_us&edition=fundamental","pubTime":"2026-01-30 18:00","pubTimestamp":1769767228,"startTime":"0","endTime":"0","summary":"Jefferies initiated coverage of enGene (ENGN) with a Buy rating and $28 price target The company is running a pivotal high-risk non-muscle invasive...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/engene-initiated-with-a-buy-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/engene-initiated-with-a-buy-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2605438059","title":"enGene Holdings Issues 2026 Warrants to Purchase Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605438059","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605438059?lang=en_us&edition=fundamental","pubTime":"2026-01-22 05:07","pubTimestamp":1769029628,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. announced the issuance of 2026 Closing Date Warrants to purchase common shares. The warrants were issued in connection with a loan agreement, with an aggregate of 40,850 warrants issued to lenders on the closing date. Each warrant has an exercise price of $9.18 per share and is exercisable for seven years from issuance. The total maximum number of 2026 Warrants that may be issued under the agreement is 204,248, representing 1.50% of the total loan commitment amount divided by the exercise price. The transaction was conducted as an unregistered sale of equity securities pursuant to Section 4 of the Securities Act of 1933.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL4XkLfq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2605424051","title":"enGene Holdings  - Secures up to $100 Mln for Detalimogene Development & Commercialization for Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2605424051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605424051?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:37","pubTimestamp":1768948649,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL1CD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2605142473","title":"enGene Announces Expanded $125 Million Debt Facility With Hercules Capital, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605142473?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:37","pubTimestamp":1768948649,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL1CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2605142413","title":"enGene Secures Expanded $125 Million Debt Facility from Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605142413?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:35","pubTimestamp":1768948516,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc., a clinical-stage genetic medicines company, has announced an amendment to its existing loan and security agreement with Hercules Capital, Inc., increasing its debt facility to up to $125 million. Under the revised terms, enGene has received an initial $25 million to refinance existing debt, with access to three additional tranches totaling $75 million contingent on achieving certain clinical, regulatory, and commercial milestones. An additional tranche of up to $25 million may be made available at Hercules' discretion. The funding strengthens enGene’s balance sheet as it prepares for a Biologics License Application to the FDA for detalimogene voraplasmid in the second half of 2026 and a potential commercial launch in 2027. All outstanding principal and accrued interest are to be repaid by January 1, 2030, unless extended under the loan agreement terms.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL8gJ3Yb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4135","HTGC","BK4139"],"gpt_icon":0},{"id":"2593530564","title":"EnGene Fiscal 2025 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2593530564","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593530564?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:12","pubTimestamp":1766441578,"startTime":"0","endTime":"0","summary":"EnGene  reported a fiscal 2025 net loss late Monday of $2.29 per diluted share, widening from a loss of $1.46 a year earlier.Analysts polled by FactSet expected a loss of $2.10.Cash, cash equivalents and marketable securities totaling $342.4 million, including proceeds from a November public offering, are expected to fund operations into the second half of 2028.Following discussions with the US Food and Drug Administration on its statistical analysis plan and the accumulation of 12-month complete response data, enGene said it expects to provide a data update on the Legend trial's pivotal cohort in the second half of 2026.The company also said it plans to submit a biologics license application for detalimogene for bacillus calmette-guerin unresponsive non-muscle-invasive bladder cancer in H2 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2593458566","title":"enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458566","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458566?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:04","pubTimestamp":1766437483,"startTime":"0","endTime":"0","summary":"enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.3 percent. This is a 114.71 percent decrease over losses of $(0.34) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/12/49549264/engene-holdings-q4-eps-0-73-misses-0-57-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2593583784","title":"enGene reports FY net loss of USD 117.3 million, more than double year-on-year","url":"https://stock-news.laohu8.com/highlight/detail?id=2593583784","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593583784?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437403,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. reported its full year  financial results for the period ended October 31, 2025. The company posted a net loss of USD 117.3 million for the year. Total operating expenses for the period were USD 123.2 million, including research and development expenses of USD 94.5 million and general and administrative expenses of USD 28.7 million. Net loss per share, basic and diluted, was USD 2.29. As of October 31, 2025, enGene Holdings Inc. reported cash, cash equivalents, and marketable securities of USD 202.3 million. The weighted-average number of common shares outstanding, basic and diluted, was 51,119,479 for the year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL7QrwSq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2593458607","title":"enGene Holdings Inc - Cash and Marketable Securities Plus Proceeds From Nov Financing Expected to Provide Cash Runway Into 2H 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458607?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUAKX7C8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2593583224","title":"Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2593583224","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593583224?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437380,"startTime":"0","endTime":"0","summary":"Completed enrollment in LEGEND's pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ. Reported preliminary 6-month complete response rate (62%) in pivotal cohort patients enrolled under amended LEGEND protocol. enGene selected for FDA's CDRP Program to support CMC readiness. Cash and marketable securities plus proceeds from November financing expected to provide cash runway into 2H 2028. \"We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the first choice therapy in BCG-unresponsive NMIBC if approved,\" said Ron Cooper, President and Chief Executive Officer. \"With recent acceptance into FDA's CDRP program and a cash position of $342.4 million, extending our runway into the second half of 2028, we are entering the new year laser-focused on scaling our organization in prepar","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","BK4135","LU2237443549.SGD","LU2746668974.SGD","BK4139","R","LU2237443978.SGD","IE00BHPRN162.USD","LU0149725797.USD","LU2746668461.USD","LU0971096721.USD","LU2237443382.USD","IE00BZ1G4Q59.USD","CR","DDX","ENGN","CMC","BK4022","LU2237443622.USD","LU2237443895.HKD","LU0170899867.USD","IE00BKVL7J92.USD","TRAE","IE00BFXG1179.USD","BCG","LU1363072403.SGD","BK4232","LU0882574139.USD","BK4006","LU0267386448.USD","BK4161","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2588056337","title":"EnGene Says US FDA Selects Detalimogene for Manufacturing Pilot Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056337","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056337?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:44","pubTimestamp":1764683062,"startTime":"0","endTime":"0","summary":"EnGene (ENGN) said Tuesday that the US Food and Drug Administration selected detalimogene for its chemistry, manufacturing and controls development and readiness pilot program.Detalimogene is an inves","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2588555320","title":"BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2588555320","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588555320?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:18","pubTimestamp":1764681501,"startTime":"0","endTime":"0","summary":"BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing ReadinessDec 2 (Reuters) - enGene Holdings Inc ENGN.O:ENGENE’S DETALIMOGENE SELECTED FOR FDA MANUFACTU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2588058033","title":"enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058033","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058033?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:47","pubTimestamp":1764679656,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. has announced positive preliminary results from the pivotal cohort of its LEGEND trial studying detalimogene voraplasmid  in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer  with carcinoma in situ  with or without concomitant papillary disease. The results showed an improved complete response rate of 62% at six months. Safety data from 125 patients demonstrated a favorable tolerability profile, with low rates of treatment-related adverse events (42%) and dose interruptions . The company has not specified if these results have already been presented at a scientific meeting or will be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL4149Bc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2588676058","title":"enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2588676058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588676058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:30","pubTimestamp":1764678620,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2588058972","title":"enGene Holdings - FDA Selects Detalimogene Voraplasmid to Participate in Chemistry, Manufacturing, & Controls  Development & Readiness Pilot Pprogram","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058972?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:30","pubTimestamp":1764678620,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2586535478","title":"enGene Holdings Inc. to Present at Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2586535478","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586535478?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:30","pubTimestamp":1764073816,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc., a clinical-stage genetic medicines company, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET. Chief Strategy and Operations Officer Alex Nichols, Ph.D., is scheduled to deliver the presentation, which will be accessible via webcast on the enGene website and archived for 90 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6xsmTn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","ENGN","BK4127","BK4139"],"gpt_icon":0},{"id":"2584924674","title":"enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924674","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924674?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:28","pubTimestamp":1763573315,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - enGene Holdings Inc ::*ENGENE HOLDINGS FILES FOR OFFERING OF COMMON SHARES, SIZE NOT DISCLOSED - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 12-NOV-202521:55:30 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDb5dKf0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2583055325","title":"enGene Holdings Inc : Leerink Partners Cuts Target Price to $19 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2583055325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583055325?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:21","pubTimestamp":1763122901,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ169:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":68,"code":"91000000","status":"200"}]}}